Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
₹ 285.65
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Very strong margins and returns
Data is available to registered users only
Data is available to registered users only
About
Gujarat Themis Biosyn Ltd. operates as a pharmaceutical company. The firm engages in the manufacture of drugs. Its products include Rifamycin and Lovastatin. The company was founded on December 11, 1981 and is headquartered in Mumbai, India.
Company Valuation
From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks. In particular, the stock is overpriced on P/E, 'expensive
Data is available to registered users only
Buy
Sell